Focused On-demand Library for Sodium-dependent neutral amino acid transporter SLC6A17

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9H1V8

UPID:

S6A17_HUMAN

Alternative names:

Sodium-dependent neurotransmitter transporter NTT4; Solute carrier family 6 member 17

Alternative UPACC:

Q9H1V8; A6NEA8; A8K1R7; B9EIR5; Q5T5Q9

Background:

The Sodium-dependent neutral amino acid transporter SLC6A17, also known as Sodium-dependent neurotransmitter transporter NTT4 and Solute carrier family 6 member 17, is pivotal in the transport of specific amino acids including proline, glycine, leucine, and alanine. Unlike its family counterparts, it operates independently of chloride ions, highlighting a unique mechanism of action.

Therapeutic significance:

SLC6A17's association with Intellectual developmental disorder, autosomal recessive 48, characterized by intellectual disability, progressive tremor, and speech impairment, underscores its potential as a therapeutic target. Understanding the role of SLC6A17 could open doors to potential therapeutic strategies.